Serum Institute of India seeks permission for Phase-3 trial of Covovax as booster dose in children aged 2 to 18 years
The Serum Institute of India (SII) has sought permission from the country’s drug regulator to conduct Phase-3 trial to evaluate the safety and immunogenicity of its COVID-19 vaccine Covovax as a booster dose in children aged two to 18 years, official sources said on Sunday. The Drugs Controller General of India (DCGI) had granted permission … Read more